# LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures

> **NCT02548143** · PHASE3 · COMPLETED · sponsor: **Laboratoire français de Fractionnement et de Biotechnologies** · enrollment: 12 (actual)

## Conditions studied

- Hemophilia

## Interventions

- **BIOLOGICAL:** Coagulation Factor VIIa (Recombinant)

## Key facts

- **NCT ID:** NCT02548143
- **Lead sponsor:** Laboratoire français de Fractionnement et de Biotechnologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-25
- **Primary completion:** 2017-08-06
- **Final completion:** 2017-08-31
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2022-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02548143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02548143, "LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02548143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*